|
Match
|
Document |
Document Title |
|
|
8173384 |
Methods for analyzing or processing a heparin sample
The invention relates to methods and products for analyzing or processing a heparin sample. In one embodiment, the methods comprise contacting the sample with heparinase I, heparinase II and...
|
|
|
8163496 |
Methods and kits for measuring von Willebrand factor
Methods and kits for measuring levels of von Willebrand factor function in a sample without using a platelet aggregation agonist, such as ristocetin, comprising recombinant glycoprotein Ibα having ...
|
|
|
8163513 |
Method for determining the total clotting activity of a blood or plasma sample
The invention relates to a method for determining the total clotting activity of a blood or plasma sample, characterized in that a highly specific, reversible thrombin inhibitor is added to a blood...
|
|
|
8133696 |
Method for determining thrombin activity
Methods and kits to determine thrombin activity are provided. They have the great advantage that there is no need to measure the whole calibrator curve in each individual medium, since a...
|
|
|
8129135 |
Method for diagnosing cardiovascular diseases
Method for diagnosing a cardiovascular disease in an individual comprising the steps of: providing a sample of an individual; determining the amount of cytokeratin-18 (CK-18) or fragments thereof...
|
|
|
8129195 |
Method for the production of an analytical element
A method is provided for producing an analytical element comprising at least one test field for analyzing a liquid sample, wherein provision is made for a carrier on which a polymer fabric is...
|
|
|
8124025 |
Membrane system for blood coagulation testing
Articles for testing a coagulation process in whole blood.
|
|
|
8114633 |
Methods for differentiating plasma-derived protein from recombinant protein in a sample
The present invention relates, in general, to methods for detecting and quantitating plasma-derived protein and recombinant protein in a sample based on the difference in protein glycosylation,...
|
|
|
8076144 |
Protocol for risk stratification of ischemic events and optimized individualized treatment
A hemostasis analyzer, such as the Thrombelastograph® (TEG®) hemostasis analyzer is utilized to measure continuously in real time, the hemostasis process from the initial fibrin formation, t...
|
|
|
8062591 |
Clinical laboratory test apparatus and clinical laboratory test system
The clinical laboratory test apparatus includes: an analyzing unit for analyzing a specimen; a reception part for receiving specimen information before analysis of the specimen; a discrimination...
|
|
|
8058023 |
Assessment of cardiac health and thrombotic risk in a patient
The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to...
|
|
|
8048990 |
Modified vitamin K-dependent polypeptides
The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot...
|
|
|
8021854 |
Method of treating vascular disease
A method for attenuating the incidence and severity of endovascular disease, arrhythmias and malignancy via a reduction in the total circulating platelet volume is presented. The method will...
|
|
|
8008086 |
Protocol for monitoring direct thrombin inhibition
A hemostasis analyzer, such as the Thrombelastograph® (TEG®) hemostasis analyzer is utilized to measure continuously in real time, the hemostasis process from the initial fibrin formation, t...
|
|
|
7981597 |
Method for preparing agglutinatable, fixed platelet fragments
The present invention relates to a method for preparing agglutinatable platelet fragments, in which native platelets are treated with ultrasound and a fixative. The platelet fragments are suitable...
|
|
|
7977106 |
Method for assaying coagulation in fluid samples
This invention is a disposable cartridge for use at the patient side to perform traditional coagulation assays on fresh whole blood or blood derivative samples. The cartridge, in use with an...
|
|
|
7947505 |
Method for testing efficacy of antithrombotic agent
The present invention provides a method for testing quickly and easily the manner in which an antithrombotic agent inhibits the acceleration of blood coagulation when a platelet agonist causes...
|
|
|
7943333 |
Diagnostic method for identifying carriers of the Marburg I variant of factor VII-activating protease (FSAP) on the basis of differential modulation of FSAP activity
The present invention relates to a diagnostic method for identifying persons with genetically related hetero- or homozygous expression of the MR I variant of factor VII-activating protease (FSAP)....
|
|
|
7939288 |
Method for differentiating between factor XIII deficiency states and fibrinogen deficiency states by means of thrombelastographic techniques
The invention relates to a method for determining a factor XIII deficiency, a method for determining a fibrinogen deficiency, and a method for differentiating between a factor XIII deficiency and a...
|
|
|
7939329 |
Protocol for risk stratification of ischemic events and optimized individualized treatment
A hemostasis analyzer, such as the Thrombelastograph® (TEG®) hemostasis analyzer is utilized to measure continuously in real time, the hemostasis process from the initial fibrin formation, t...
|
|
|
7935498 |
Methods for identifying patients with increased risk of an adverse cardiovascular event
Methods, compositions and kits are disclosed for identifying patients with an increased risk of experiencing an adverse cardiovascular event where the patient is undergoing aspirin antiplatelet...
|
|
|
7927626 |
Process of making flowable hemostatic compositions and devices containing such compositions
The present invention is directed to processes of making flowable hemostatic compositions and devices that include the flowable hemostatic composition disposed therein, where a volume of a...
|
|
|
7923255 |
Method of detecting platelet thrombosis or organ failure
A method of detecting platelet thrombosis or organ failure in a patient suffering from disseminated intravascular coagulation (DIC) or systemic inflammatory response syndrome (SIRS), comprising...
|
|
|
7923217 |
Specificity in the determination of antithrombin
Methods and reagents for determining antithrombin III (AT) in body fluids by adding an AT binding partner to the sample and determining the free AT binding partner.
|
|
|
7906299 |
Assay for low molecular weight heparin
A prothrombin time reagent for determination of low molecular weight heparin in fresh whole blood and in anti-coagulant treated blood is provided. The reagent is composed of recombinant animal...
|
|
|
7897333 |
Reagent for measuring clotting time and method for manufacturing the reagent
A reagent for measuring clotting time is described. The reagent comprises a complex of a phospholipid and a recombinant tissue factor obtained by using an insect or a cultured insect cell as a...
|
|
|
7883698 |
Isolation and preservation of fetal hematopoietic and mesencymal system cells from non-controversial materials and/or tissues resulting from miscarriages and methods of therapeutic use
The present invention is directed to compositions of fetal hematopoietic stem and progenitor cells and stromal (mesencymal) cells derived from second trimester (16-20 weeks gestation) miscarriages,...
|
|
|
7867771 |
Reagent for measuring clotting time and method for stabilizing tissue factor
The present invention provides a reagent for measuring clotting time including a nonionic surfactant, a nickel ion and a tissue factor. A method for stabilizing a tissue factor, and use of a...
|
|
|
7829294 |
Anti-human soluble fibrin monoclonal antibody and immunological assay method using the antibody
The present invention is directed to a monoclonal antibody against a soluble fibrin, which specifically recognizes a conformation-changed site newly occurred in a C-terminal region of an Aα-chain ...
|
|
|
7807107 |
Particle agglutination-evaluating container
A particle agglutination-evaluating container for immunological analysis, based on an agglutinate formed in an agglutination reaction between an antibody- or antigen-containing sample and...
|
|
|
7803569 |
Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis and methods of detecting FSAP and FSAP mutations
An arterial thrombosis risk factor comprising one or more of the identified mutants of coagulation factor VII activating protease (FSAP) is described. In addition, diagnostic determination methods...
|
|
|
7803570 |
Method for determining the concentration of thrombin inhibitors
The invention relates to a method for determining the concentration of thrombin inhibitors in a non-turbid body liquid or a non-turbid extract from a body liquid. It comprises the following steps....
|
|
|
7790409 |
Blood coagulation accelerator and container for blood examination
The present invention provides a blood coagulation accelerator excellent under severe conditions at ordinary or higher temperatures and capable of exhibiting high blood coagulation performance...
|
|
|
7790410 |
Method and apparatus for determining hemocompatibility
Provided herein are techniques for screening materials for hemocompatibility. Hemocompatible materials may be advantageous when incorporated into devices that may come into direct contact with...
|
|
|
7785891 |
Device and methods for identifying and treating aspirin non-responsive patients
The present invention relates to methods and compositions for identifying and treating subjects in need of antithrombotic therapies but who are not responsive to aspirin.
|
|
|
7785820 |
Method for automatically determining the endogenous thrombin potential
The present invention relates to a method for automatically determining the endogenous thrombin potential of a blood or plasma sample.
|
|
|
7771996 |
FVII or FVIIa variants
Variants of FVII or FVIIa comprising at least one amino acid modification in position 196, 237 or 341 relative to hFVII or hFVIIa. The variants exhibit an increased clotting activity, i.e. reduced...
|
|
|
7767459 |
Method for determining prothrombin time
A method for determining prothrombin time of a plasma or whole blood sample includes measuring prothrombin time for at least two different dilutions for a test sample to determine tmin or INRmin....
|
|
|
7767458 |
Method for determining coagulation activation and device for carrying out said method
A method is disclosed of assaying circulating microparticles contained in a sample of whole blood or blood plasma from a patient to determine the patient's ability to generate thrombin or Factor Xa...
|
|
|
7759082 |
Electroprocessed fibrin-based matrices and tissues
The invention is directed to formation and use of electroprocessed fibrin as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can...
|
|
|
7759083 |
Screening method for a growth inhibitor or promoter of a vascular smooth muscle cell
It was found that TAT which has not been known biological activity has a role as a new blood vessel smooth muscle proliferation factor, and then a screening method vascular of an inhibitor or...
|
|
|
7754489 |
Protocol for risk stratification of ischemic events and optimized individualized treatment
A hemostasis analyzer, such as the Thrombelastograph® (TEG®) hemostasis analyzer is utilized to measure continuously in real time, the hemostasis process from the initial fibrin formation, t...
|
|
|
7745224 |
Procedure for the standardization of coagulation tests
The present invention lies in the field of coagulation diagnosis and relates to a procedure for the standardization of coagulation tests, where calibrators are used to which a discrete standard...
|
|
|
7741124 |
Detection procedures for fibrinogen and/or fibrinogen derivatives
Described are determination procedures for fibrinogen and/or fibrinogen-derivatives by matrix-independent turbidimetry. In the FIFTA called procedure the fibrinogen activity is preferably...
|
|
|
7732213 |
Method of evaluating patient hemostasis
A hemostasis analyzer, such as the Thrombelastograph® (TEG®) hemostasis analyzer is utilized to measure continuously in real time, the hemostasis process from the initial fibrin formation, t...
|
|
|
7727736 |
Soluble phospholipids for use in clotting factor assays
The present invention provides a soluble phospholipid reagent and assays of clotting activity using the same. The methods of the invention can be used to carry out any clotting assay or other assay...
|
|
|
7723064 |
Methods for monitoring patients for efficacy of an antiplatelet therapy regimen
Methods are disclosed for monitoring patients utilizing Mean Platelet Component values during therapeutic intervention.
|
|
|
7718412 |
Hemostatic compositions containing sterile thrombin
The present invention includes sterilized hemostatic compositions that contain a continuous, biocompatible liquid phase having a solid phase of particles of a biocompatible polymer suitable for use...
|
|
|
7718763 |
Substrate polyeptides for von Willebrand factor cleaving protease ADAMTS-13
The present invention relates to specific substrates for a von Willebrand factor cleaving enzyme, ADAMTS-13, as well as to diagnosis of ADAMTS-13 deficient patients, diagnostic compositions, and...
|
|
|
7682808 |
Coagulation and fibrinolytic cascades modulator
A thromboplastin reagent comprises (i) TF, (ii) a phospholipid, and (iii) a polyP TFPI blocker.
|